Positive interim results from the Phase III DESTINY-Breast09 trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), ...

DATROWAY ® (datopotamab deruxtecan) has been approved in the European Union (EU) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative ...

In the Phase III DESTINY-Breast09 trial, Enhertu (trastuzumab deruxtecan) and Perjeta (pertuzumab) significantly improved ...

Another possible mechanism of action is the preferential exertion of antibody- dependent cellular cytotoxicity on HER2-overexpressing cancer cells. [62] Trastuzumab contains an immunoglobulin G1 ...

Cancer Research publishes impactful original studies, reviews, and opinion pieces of high significance to the broad cancer research community. Cancer Research seeks manuscripts that offer conceptual ...

Israel and Turkey have recently discussed creating a coordination mechanism in Syria in efforts to prevent friction, a source familiar with details told The Jerusalem Post on Wednesday.

The Medicines and Healthcare products Regulatory Agency (MHRA) has today (9 April 2025) approved trastuzumab deruxtecan (Enhertu) to treat people with solid tumours that have mutations in human ...

Kate Nalepinski is a Newsweek journalist based in New York City. Kate joined Newsweek in May 2024. She is a graduate of Ithaca College. As generative AI continues to evolve, social media users are ...

First approval in the EU for Daiichi Sankyo and AstraZeneca’s DATROWAY based on TROPION-Breast01 trial showing 37% reduction in the risk of disease progression or death versus chemotherapy ...